Lelia T. Halloran

Detail oriented, organized central monitor with 11 years’ cumulative experience looking to further my career in clinical research.

• 10/2018, Certified Clinical Research Coordinator, ACRP
• 09/2018, Basic Life Support (CPR and AED) Program, American Heart Association

• Novocart 3D Autologous Chondrocyte Implant System, Aesculap Biologics, LLC, (2015-2017), Prospective, randomized, controlled, multicenter, phase-III clinical study evaluating the safety and effectiveness of Novocart 3D compared to the standard procedure microfracture for treatment of articular cartilage defects in the knee.
• NUsurface Meniscus Implant, Active Implants, LLC, (2015 - 2017), Randomized, multicenter, prospective, interventional clinical trial evaluating the effectiveness of the NUsurface device compared to standard of care treatments.
• An Investigation of ReNu Knee Injection, NuTech Medical, (2015 - 2017), Prospective, randomized study evaluating the efficacy of ReNu in patients with Kellfren-Lawrence grade II-III osteoarthritis.
• PROGRESS IV Clinical Trial, Zimmer Biomet, (2017), Double-blind, multicenter, randomized, controlled trial for patients with early to moderate symptomatic knee osteoarthritis in one knee who failed previous conservative therapy.
• Single-use Efficiency Instruments With Patient Specific Technique (MyKnee) Versus Traditional Metal Instruments With Conventional Surgical Technique, Medacta USA, (2017 - 2018), Multi-center, Prospective, Randomized Study Comparing Surgical and Economic Parameters of Total Knee Replacement Performed With Single-use Efficiency Instruments With Patient Specific Technique (MyKnee) Versus Traditional Metal Instruments With Conventional Surgical Technique.
• Alkermes ALK8700-A302, Alkermes, (2018 - 2019), A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate
• Alkermes ALK8700-A301, Alkermes, (2018 - 2021), A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis
• RESTORE, Lundbeck NA Ltd., (2018 - 2021), A clinical study of patients with symptomatic neuRogenic orthostatic hypotEnsion to assess Sustained effecTs Of dRoxidopa therapy
• INSYTE ACP-103-037, ACADIA Pharmaceuticals, (2018 - 2021), Prospective, observational study evaluating the management of Parkinson’s Disease Psychosis in Actual Practice (The INSYTE Study).
• A0081096, Pfizer Inc., (2018 - 2020), Prospective Randomized 12-Week Controlled Study of Visual Field Change in Subjects with Partial Seizures Receiving Pregabalin or Placebo (Pro00026427).
• MASTER-2, EMD Serono, (2019 - 2021), Observational evaluation of effectiveness and patient-reported outcomes (PROs) in suboptiMAlly controlled patientS previously Taking oral or infusion disEase-modifying dRugs (DMDs) for relapsing forms of multiple sclerosis (RMS) (MASTER-2).
• CLICK-MS, EMD Serono, (2019 - 2021), Observational evaluation of effectIveness and patient-reported outcomes (PROs) in suboptimally Controlled patients previously taKing injectable disease-modifying drugs (DMDs) for relapsing forms of Multiple Sclerosis (RMS) (CLICK-MS).
• DUET (EP0092), UCB Biopharm SRL, (2019 - 2020), A multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Padsevonil as adjunctive treatment of focal-onset seizures in adult subjects with drug-resistant epilepsy.
• EP0093, UCB Biopharm SRL, (2019 - 2020), An open-label, multi-center, extension study to evaluate the safety and efficacy of Padsevonil as adjunctive treatment of focal-onset seizures in adult subjects with drug-resistant epilepsy.
• ACP-103-063, ACADIA Pharmaceuticals, (2020 - 2021), A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson’s Disease Psychosis.
• AbbVie M15-736, AbbVie, (2020 - 2021), Advanced Parkinson's Disease: Double-Blind, Double-Dummy, Active-Controlled, Efficacy and Safety Study of ABBV-951 Versus Oral Carbidopa/Levodopa.
• TemPo2, Cerevel Therapuetics, LLC, (2020 - 2021), A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson’s Disease (TemPo-2 Trial).
• AbbVie M20-098, AbbVie, (2020 - 2021), An Open-Label Extension of Study M15-736 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects with Advanced Parkinson’s Disease.
• TemPo3, Cerevel Therapuetics, (2020 - 2021), A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson’s Disease in Levodopa-Treated Adults With Motor Fluctuations (TemPo-3 Trial).
• 324-ETD-201, SAGE Therapuetics, Inc., (2020 - 2021), A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Efficacy, Safety, and Tolerability of SAGE-324 in the Treatment of Individuals with Essential Tremor.
• GEMINI2, Genzyme Corporation, (2020 - 2021), A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio) in participants with relapsing forms of multiple sclerosis (GEMINI 2).
• TemPo4, Cerevel Therapuetics, (2021), 58-Week Open-Label Trial of Tavapadon in Parkinson’s Disease (TemPo-4 Trial)
• SUVN-G3031, Suven Life Sciences Limited, (2021 - 2022), A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
• TrilynX, EMD Serono Research & Development Institute, Inc., (2021 - 2023), A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
• PROGRESS, Incyte Corporation, (2023 - 2024), A Phase 2, Randomized, Double-Blind, Placebo-Controlled STudy to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants with Fibrodysplasia Ossificans Progressiva (PROGRESS)
• IMG-7289/MK-3543, Imago BioScienes, Inc., (2023 - 2024), A Multi-Center, Open Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Patients with Myeloproliferative Neoplasms (MPNs) Enrolled in a Prior Bomedemstat Clinical Study
• 405-201-00016, Otsuka Pharmaceutical Development & Commercialization, Inc., (2023), A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the Efficacy and Safety of Once Daily Centanafadine Capsules for the Treatment of Adolescents With Attention-deficit/Hyperactivity Disorder
• 405-201-00017, Otsuka Pharmaceutical Development & Commercialization, Inc., (2023 - 2024), A Phase 3, Multimeter, Open-label, Long-term Trial Evaluating the Long-term Safety and Tolerability of Once Daily Centanafadine Capsules in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)
• CTP2S1911A4B2, Suven Life Sciences Limited, (2024), A Phase 2a Open-Label Study Evaluating the Safety and Efficacy of Ropanicant in Participants With Moderate to Severe Major Depressive Disorder